Advertisement
New Zealand markets closed
  • NZX 50

    11,783.39
    -26.09 (-0.22%)
     
  • NZD/USD

    0.6116
    +0.0014 (+0.23%)
     
  • NZD/EUR

    0.5635
    -0.0003 (-0.05%)
     
  • ALL ORDS

    7,999.20
    -83.90 (-1.04%)
     
  • ASX 200

    7,727.60
    -84.20 (-1.08%)
     
  • OIL

    77.35
    +0.48 (+0.62%)
     
  • GOLD

    2,338.70
    +1.50 (+0.06%)
     
  • NASDAQ

    18,720.98
    +97.60 (+0.52%)
     
  • FTSE

    8,315.36
    -23.87 (-0.29%)
     
  • Dow Jones

    39,110.01
    +44.75 (+0.11%)
     
  • DAX

    18,594.40
    -96.92 (-0.52%)
     
  • Hang Seng

    18,608.94
    -259.77 (-1.38%)
     
  • NIKKEI 225

    38,646.11
    -457.11 (-1.17%)
     
  • NZD/JPY

    95.9770
    +0.2750 (+0.29%)
     

UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study

Unity Biotechnology, Inc.
Unity Biotechnology, Inc.

-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET-

-Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023-

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325, as a potential treatment solution to address the unmet medical need present in age-related diseases of the eye on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET. Robert B. Bhisitkul, M.D., Ph.D., of University of California San Francisco School of Medicine will review data from the Phase 2 BEHOLD study in diabetic macular edema, followed by an update on upcoming data readouts from the Phase 2 ENVISION study in patients with wet age-related macular degeneration. The Company expects to have 16- and 24-week safety and efficacy data from the ENVISION study in the first quarter of 2023.

ADVERTISEMENT

A live question and answer session will follow the formal presentation. The webcast can be accessed in the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations” or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, under “Events and Presentations.”

About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact
Evoke Canale
Katherine Smith
Katherine.smith@evokegroup.com

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com

Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of the results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission on November 8, 2022, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.